___

• • Anand, P., & Singh, B. (2013). Cite as a review on cholinesterase inhibitors for Alzheimer’s disease. Archives of Pharmacal Research, 36 (4), 375–399.
• • Banks, W.A. (2009). Characteristics of compounds that cross the blood-brain barrier. BMC Neurology, 9 (1), 1–5.
• • Chang, T.S. (2009). An updated review of tyrosinase inhibitors. International Journal of Molecular Sciences, 10, 2440–2475.
• • Choi, J.S., Islam, M.N., Ali, M.Y., Kim, E.J., Kim, Y.M., & Jung, H.A. (2014). Effects of C-glycosylation on anti-diabetic, anti-Alzheimer’s disease and anti-inflammatory potential of apigenin. Food and Chemical Toxicology, 64, 27–33.
• • Dajas, F., Rivera-Megret, F., Blasina, F., Arredondo, F., Abin-Carriquiry, J.A., Costa, G., Echeverry, C., Lafon, L., Heizen, H., Ferreira, M., & Morquio, A. (2003). Neuroprotection by flavonoids. Brazilian Journal of Medical and Biological Research, 36, 1613–1620.
• • Ellman, G. L., Courtney, K. D., Andres, V., & Feather-Stone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7, 88–95.
• • Erdogan Orhan, I., Khan, M.T.H. (2014). Flavonoid derivatives as potent tyrosinase inhibitors - a survey of recent findings between 2008-2013. Current Topics in Medicinal Chemistry, 14(12), 1486–1493.
• • Faria, A., Mateus, N., & Calhau, C. (2012). Flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions. Nutrition and Aging, 1, 89–97.
• • Grutzendler, J., & Morris, J. C. (2001). Cholinesterase inhibitors for Alzheimer’s disease. Drugs, 61(1), 41–52.
• • He, M., Min, J. W., Kong, W. L., He, X. H., Li, J. X., & Peng, B. W. (2016). A review on the pharmacological effects of vitexin and isovitexin. Fitoterapia, 115, 74–85.
• • Jung, H. A., Karki, S., Kim, J. H., & Choi, J. S. (2015). BACE1 and cholinesterase inhibitory activities of Nelumbo nucifera embryos. Archives of Pharmacal Research, 38, 1178–1187.
• • Katalinic, M., Rusak, G., Barovic, J. D., Sinko, G., Jelic, D., Antolovic, R., & Kovarik, Z. (2010). Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. European Journal of Medicinal Chemistry, 45, 186–192.
• • Komloova, M., Musilek, K., Horova, A., Holas, O., Dohnal, V., Gunn- Moore, F., & Kuca, K. (2011). Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early Myasthenia gravis treatment. Bioorganic & Medicinal Chemistry Letters, 21 (8), 2505–2509.
• • Lima, L. K. F., Pereira, S. K. S., Junior, R. S. S., Santos, F. P. S., Nascimento, A. S., Feitosa, C. M., Figuerêdo, J. S., Cavalcante, A. N., Araújo, E. C. C., & Rai, M. (2018). A brief review on the neuroprotective mechanisms of vitexin. BioMed Research International, 2018, 1–8. https://doi.org/10.1155/2018/4785089.
• • Masuda, T., Yamashita, D., Takeda, Y., & Yonemori, S. (2005). Screening for tyrosinase inhibitors among extracts of seashore plants and identification of potent inhibitors from Garcinia subelliptica. Bioscience, Biotechnology, and Biochemistry, 69, 197–201.
• • Meng, X.Y., Zhang, H.X., Mezei, M., & Cui, M. (2011). Molecular Docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157.
• • Morris, G. M., & Lim-Wilby, M. (2008). Molecular docking. Methods in Molecular Biology, 443, 365–382.
• • Nordberg, A., & Svensson, A. L. (1998). Cholinesterase inhibitors in the treatment of Alzheimer’s disease A comparison of tolerability and pharmacology. Drug Safety, 19(6), 465–480.
• • Seo, S.Y., Sharma, V. K., & Sharma, N. (2003). Mushroom tyrosinase: Recent prospects. Journal of Agricultural and Food Chemistry, 51, 2837–2853.
• • Sheeja Malar, D., Shafreen, R. B., Karutha Pandian, S. T., & Devi, K. P. (2017). Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant Grewia tiliaefolia -An in vitro and in silico study. Pharmaceutical Biology, 55(1), 381–393.
• • Spandana, K. M. A., Bhaskaran, M., Karri, V. V.S. N. R., & Natarajan, J. (2020). A comprehensive review of nano drug delivery system in the treatment of CNS disorders. The Journal of Drug Delivery Science and Technology. https://doi.org/10.1016/j.jddst.2020.101628.
• • Ye, Y., Chou, G. X., Wang, H., Chu, J. H., & Yu, Z. L. (2010). Flavonoids, apigenin and icariin exert potent melanogenic activities in murine B16 melanoma cells. Phytomedicine, 18, 32–35.
• • Zhou, X., Wang, F., Zhou, R., Song, X., & Xie, M. (2017). Apigenin: A current review on its beneficial biological activities. Journal of Food Biochemistry, 41, e12376.
• • Zolghadri, S., Bahrami, A., Khan, M. T. H., Munoz-Munoz, J., Garcia- Molina, F., Garcia-Canovas, F., & Saboury, A. A. (2019). A comprehensive review on tyrosinase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 34 (1), 279–309.